Aclaris Therapeutics Inc (NASDAQ:ACRS) price target set to $50.00 by Cantor Fitzgerald

Analyst Ratings For Aclaris Therapeutics Inc (NASDAQ:ACRS)

Story continues below

Today, Cantor Fitzgerald set its price target on Aclaris Therapeutics Inc (NASDAQ:ACRS) to $50.00 per share.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) is Buy with a consensus target price of $48.50 per share, a potential 183.13% upside.

Some recent analyst ratings include

  • 2/8/2018-Guggenheim initiated coverage with a Buy rating.
  • 9/8/2017-JMP Securities Reiterated Rating of Outperform.
  • 7/31/2017-Jefferies Financial Group Reiterated Rating of Buy.

Recent Insider Trading Activity For Aclaris Therapeutics Inc (NASDAQ:ACRS)
Aclaris Therapeutics Inc (NASDAQ:ACRS) has insider ownership of 17.00% and institutional ownership of 99.09%.

  • On 6/12/2018 Kamil Ali-Jackson, Insider, sold 5,000 with an average share price of $20.00 per share and the total transaction amounting to $100,000.00.
  • On 5/18/2018 Kamil Ali-Jackson, Insider, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
  • On 5/16/2018 Andrew Kenneth William Powell, Director, bought 500 with an average share price of $19.12 per share and the total transaction amounting to $9,560.00.
  • On 5/7/2018 Frank Ruffo, CFO, bought 1,250 with an average share price of $18.22 per share and the total transaction amounting to $22,775.00.
  • On 4/6/2018 Frank Ruffo, CFO, bought 1,250 with an average share price of $16.59 per share and the total transaction amounting to $20,737.50.
  • On 4/6/2018 Stephen A Tullman, Director, bought 26,700 with an average share price of $16.54 per share and the total transaction amounting to $441,618.00.
  • On 4/5/2018 Neal Walker, Insider, bought 10,000 with an average share price of $16.75 per share and the total transaction amounting to $167,500.00.

About Aclaris Therapeutics Inc (NASDAQ:ACRS)
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Recent Trading Activity for Aclaris Therapeutics Inc (NASDAQ:ACRS)
Shares of Aclaris Therapeutics Inc closed the previous trading session at 17,24 −0,83 4,62 % with shares trading hands.

An ad to help with our costs